Innocoll Biotherapeutics, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, successfully refinanced its existing term loan facility with a new $125 million term loan provided by funds managed by Oaktree Capital Management. The new term loan meaningfully strengthens Innocoll’s financial flexibility and enables the.
$125 million refinancing substantially improves Innocoll's liquidity, enabling further investment in pharmaceutical technology portfolio and growth plan Innocoll Biotherapeutics plc, a specialty pharmaceutical